The Novel Protease-Activated Receptor 1 Antagonist Vorapaxar as a Treatment for Thrombosis in Afibrinogenemia

Bernard Tawfik; Elizabeth Pollard; Yu-Min Shen

doi:10.1055/s-0038-1654715

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2018; 44(04): 404-406
DOI: 10.1055/s-0038-1654715

Letter to the Editor

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Novel Protease-Activated Receptor 1 Antagonist Vorapaxar as a Treatment for Thrombosis in Afibrinogenemia

Bernard Tawfik

¹Division of Hematology and Oncology, University of Texas Southwestern, Dallas, Texas

,

Elizabeth Pollard

¹Division of Hematology and Oncology, University of Texas Southwestern, Dallas, Texas

,

Yu-Min Shen

¹Division of Hematology and Oncology, University of Texas Southwestern, Dallas, Texas

› Author Affiliations

Abstract

Full Text

References

References
1 Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14 (06) 1151-1158
2 Santoro C, Massaro F, Venosi S. , et al. severe thrombotic complications in congenital afibrinogenemia: a pathophysiological and management dilemma. Semin Thromb Hemost 2016; 42 (05) 577-582
3 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4 (10) 2115-2129
4 Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012; 130 (Suppl. 02) S7-S11
5 Chevalier Y, Dargaud Y, Argaud L, Ninet J, Jouanneau E, Négrier C. Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report. Thromb Res 2011; 128 (03) 296-298
6 Mukaddam A, Patil R, Jadli A, Chandrakala S, Ghosh K, Shetty S. Paradoxical bleeding and thrombosis in a patient with afibrinogenemia and fibrinogen Mumbai mutation. Am J Clin Pathol 2015; 143 (05) 755-757
7 Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9 (09) 1687-1704
8 Casini A, de Moerloose P. ; Congenital Fibrinogen Disorders Group. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia 2016; 22 (06) 898-905
9 de Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I). Thromb Haemost 2002; 88 (02) 253-258
10 Korte W, Poon M-C, Iorio A, Makris M. Thrombosis in inherited fibrinogen disorders. Transfus Med Hemother 2017; 44 (02) 70-76
11 Bonaca MP, Scirica BM, Craeger MA. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013; 127 (14) 1522-1529